Researchers leverage their understanding of molecular motors to improve nanoscale artificial motors, aiming to bridge the ...

Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.

An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower ...

Funding for motor neurone disease (MND) research has received a boost through a unique fundraising initiative involving vintage trucks. Dr. Lotta Oikari, a senior research officer at QIMR Berghofer ...

New guidelines will help doctors identify patients with a common memory-loss syndrome that is often misdiagnosed as Alzheimer's disease in older adults. The diagnostic criteria for limbic-predominant ...

Investing.com -- Shares of Ionis Pharmaceuticals (NASDAQ: IONS) climbed 7% today after the company announced that regulatory agencies in the United States and Europe have accepted applications for a ...

President Biden in 2022 announced Admiral Linda Fagan as the new commandant of the U.S. Coast Guard making her the first ...

The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, ...

Fernando Alonso, Driver Against the odds, Prince Harry has won a landmark victory Your protein needs change as you get older.

We are pleased to announce that our applications for the higher dose regimen of nusinersen are now under review in the US and Europe,” said Stephanie Fradette, Pharm.D., Head of the Neuromuscular ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

New guidelines will help doctors identify patients with a common memory-loss syndrome that is often misdiagnosed as Alzheimer's disease in older adults.